🇺🇸 FDA
Pipeline program

Selinexor

GCC-003

Phase 2 small_molecule completed

Quick answer

Selinexor for Carcinoma, Neuroendocrine is a Phase 2 program (small_molecule) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Karyopharm Therapeutics
Indication
Carcinoma, Neuroendocrine
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials